TY - JOUR
T1 - The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology
T2 - A Brief Report
AU - Chung, Jun Ku
AU - Plitman, Eric
AU - Nakajima, Shinichiro
AU - Caravaggio, Fernando
AU - Shinagawa, Shunichiro
AU - Iwata, Yusuke
AU - Gerretsen, Philip
AU - Kim, Julia
AU - Takeuchi, Hiroyoshi
AU - Patel, Raihaan
AU - Chakravarty, M. Mallar
AU - Strafella, Antonio
AU - Graff-Guerrero, Ariel
N1 - Funding Information:
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimag- ing Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujire-bio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Neu-roRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Publisher Copyright:
© 2017 - IOS Press and the authors. All rights reserved.
PY - 2017
Y1 - 2017
N2 - The clinical and structural trajectories of suspected non-Alzheimer' pathology (SNAP) remain elusive due to its heterogeneous etiology. Baseline and longitudinal clinical (global cognition, daily functioning, symptoms of dementia, and learning memory) and hippocampal volume trajectories over two years were compared between patients with amnestic mild cognitive impairment (aMCI) with SNAP with reduced hippocampal volumes (SNAPHIPPO) and aMCI patients with SNAP without reduced hippocampal volumes. SNAPHIPPO showed overall worse baseline cognitive functions. Longitudinally, SNAPHIPPO showed faster deterioration of clinical symptoms of dementia. Having both hippocampal atrophy and cortical hypometabolism without amyloid pathology may exacerbate symptoms of dementia in aMCI.
AB - The clinical and structural trajectories of suspected non-Alzheimer' pathology (SNAP) remain elusive due to its heterogeneous etiology. Baseline and longitudinal clinical (global cognition, daily functioning, symptoms of dementia, and learning memory) and hippocampal volume trajectories over two years were compared between patients with amnestic mild cognitive impairment (aMCI) with SNAP with reduced hippocampal volumes (SNAPHIPPO) and aMCI patients with SNAP without reduced hippocampal volumes. SNAPHIPPO showed overall worse baseline cognitive functions. Longitudinally, SNAPHIPPO showed faster deterioration of clinical symptoms of dementia. Having both hippocampal atrophy and cortical hypometabolism without amyloid pathology may exacerbate symptoms of dementia in aMCI.
KW - Functional decline
KW - hippocampus
KW - mild cognitive impairment
KW - suspected non-Alzheimer's pathology
UR - http://www.scopus.com/inward/record.url?scp=85029612921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029612921&partnerID=8YFLogxK
U2 - 10.3233/JAD-170098
DO - 10.3233/JAD-170098
M3 - Article
C2 - 28826178
AN - SCOPUS:85029612921
SN - 1387-2877
VL - 60
SP - 341
EP - 347
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 2
ER -
